In recent years, we have come across several patients with entecavir resistance, and it is at this point that the importance of individualized treatment is most evident. Many physicians and popular beliefs about drug resistance are to follow up regularly and to promptly combine or switch to a non-resistant antiviral drug when the virus turns positive. The question is, does this view still apply now that we have entecavir resistance in our patients? What about the patient in the reality of combining adefovir, or switching to tenofovir both in terms of price and access is still limited? In the case of normal liver function, only positive viral levels and stable disease, my advice to the patient is not to rush to switch to tenofovir and continue to take entecavir for maintenance, now the patient’s state I personally believe is a new carrier in a dosing state. The drug-resistant mutation of the virus from the point of view of evolution and symbiosis is an effort to mutate in the direction of peaceful coexistence with the patient, seeking to survive, the new mutant virus does not cause hepatitis is more likely, but at this time the patient is not suitable for discontinuation of entecavir, especially patients with severe disease before the use of drugs, arbitrary discontinuation of drugs may trigger the deterioration of the disease, because the wild-type drug-free virus inhibited by the drug is precisely the reason for your initial onset. 3 years This has also been proven to be true. Several patients have continued to take entecavir and their disease has always been in a state of normal liver function, no significant changes in ultrasound, and positive viral levels. So the reality is that before any significant breakthrough in hepatitis B medications, patients should be cautious about making arbitrary adjustments to their antiviral medications, and it is sometimes wise and realistic to stop and wait and see. For a chronic disease, the longer the stability, the better for the patient. Of course, we cannot rule out that some patients have abnormal liver function and are forced to switch to antiviral programs such as tenofovir, which must be used when it is still necessary. Now the combination of interferon treatment is also very popular.